The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

What this study is testing ClinicalTrials.gov NCT00845559 ↗

Description as written by the study sponsor.

The primary aim of this study is to evaluate the effect of exenatide on daily glycemic excursions obtained by continuous glucose monitoring system (CGMS). The CGMS summary parameters that we are most interested in include: * The percent of glucose values above 140 mg/dl and/or AUC of glucose values above 140 mg/dl * AUC of glucose values over 100 mg/dl during three days * Maximal meal-related glucose excursions * Three-day mean glucose (including low readings - below 100 mg/dl) Secondary Study Endpoints: Secondary endpoints will include: * glucose tolerance status as assessed by OGTT * Vascular function scores as assessed by PAT, FMD and step test. * Biochemical markers of vascular health, including inflammatory markers, markers of oxidative stress and microalbuminuria. * Changes in BMI

Treatments tested

• Exenatide also known as Byetta Drug

  Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.